Trial Profile
An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Alisporivir (Primary) ; EDP 239 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 08 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 19 Aug 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.